Aytu Biopharma (AYTU) Non-Current Deffered Revenue (2015 - 2017)

Aytu Biopharma (AYTU) has reported Non-Current Deffered Revenue for 3 consecutive years, with $1451.0 the latest figure, recorded in Q2 2017.

• On a quarterly basis, Non-Current Deffered Revenue fell 82.34% year-over-year to $1451.0 in Q2 2017; TTM through Jun 2017 was $1451.0, a 82.34% decrease from a year earlier, with the FY2017 full-year figure at $1451.0, down 82.34% from the prior year.
• Non-Current Deffered Revenue was $1451.0 for Q2 2017 at Aytu Biopharma, down from $3119.0 in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $425893.0 in Q2 2015 and troughed at $1451.0 in Q2 2017.
• A 3-year average of $177669.8 and a median of $8215.0 in 2016 frame the typical range for Non-Current Deffered Revenue.
• The widest YoY moves for Non-Current Deffered Revenue: up 82.34% in 2017, down 99.14% in 2017.
• Over 3 years, Non-Current Deffered Revenue stood at $383036.0 in 2015, then tumbled by 98.75% to $4787.0 in 2016, then sank by 69.69% to $1451.0 in 2017.
• The last three Non-Current Deffered Revenue figures came in at $1451.0 (Q2 2017), $3119.0 (Q1 2017), and $4787.0 (Q4 2016), per Business Quant data.